The studies tested proprietary mixtures of bacterial agents that colonize the intestinal tract and prevent C. difficile from thriving, and were reported on at the Digestive Disease Week (DDW) virtual meeting.
Though applied enema the treatment is different from the popularly known fecal transplant. Since fecal transplants involve a human donor, they are inherently variable.
Instead Rebiotix, unit of Ferring, applies RBX2660, a specific live bacteria that is delivered via enema. The other product, SER-109, is an oral mixture of Firmicutes bacterial spores, says Medpage Today article. Both showed varying degrees of success.